Mateo Mathieu, Baize Sylvain
Institut Pasteur, Université Paris Cité, Unité de biologie des infections virales émergentes, Paris, France - Centre international de recherche en infectiologie (CIRI), université de Lyon, Inserm U1111, école normale supérieure de Lyon, université Lyon 1, CNRS UMR5308, 69-007, Lyon, France.
Med Sci (Paris). 2023 Nov;39(11):855-861. doi: 10.1051/medsci/2023162. Epub 2023 Nov 29.
Arenaviruses are a global threat, causing thousands of deaths each year in several countries around the world. Despite strong efforts in the development of vaccine candidates, vaccines against Lassa fever or Bolivian and Venezuelan hemorrhagic fevers are yet to be licensed for a use in humans. In this synthesis, we present the arenaviruses causing fatal diseases in humans and the main vaccine candidates that have been developed over the past decades with an emphasis on the measles-Lassa vaccine, the first Lassa vaccine ever tested in humans, and on the MOPEVAC platform that can potentially be used as a pan-arenavirus vaccine platform.
沙粒病毒是一种全球性威胁，每年在世界上多个国家导致数千人死亡。尽管在开发候选疫苗方面付出了巨大努力，但针对拉沙热、玻利维亚出血热和委内瑞拉出血热的疫苗尚未获得用于人类的许可。在本综述中，我们介绍了导致人类致命疾病的沙粒病毒以及过去几十年开发的主要候选疫苗，重点介绍了麻疹-拉沙疫苗，这是有史以来第一种在人体中进行测试的拉沙疫苗，以及可能用作泛沙粒病毒疫苗平台的MOPEVAC平台。
